LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Search

Simulations Plus Inc

Deschisă

SectorSănătate

20.68 3.82

Rezumat

Modificarea prețului

24h

Curent

Minim

19.83

Maxim

20.74

Indicatori cheie

By Trading Economics

Venit

-70M

-67M

Vânzări

-2.1M

20M

P/E

Medie Sector

48.528

80.03

Randament dividend

0.48

Marjă de profit

-330.585

Angajați

243

EBITDA

327K

5.3M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+0.74% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.48%

2.29%

Statistici piață

By TradingEconomics

Capitalizare de piață

-7M

344M

Deschiderea anterioară

16.86

Închiderea anterioară

20.68

Sentimentul știrilor

By Acuity

56%

44%

310 / 374 Clasament în Healthcare

Simulations Plus Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 dec. 2025, 23:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec. 2025, 23:14 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec. 2025, 22:01 UTC

Principalele dinamici ale pieței

Costco Wholesale Reports Higher Monthly Sales

3 dec. 2025, 21:38 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec. 2025, 23:10 UTC

Câștiguri

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec. 2025, 23:06 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec. 2025, 22:20 UTC

Câștiguri

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec. 2025, 22:19 UTC

Câștiguri

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec. 2025, 22:17 UTC

Câștiguri

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec. 2025, 22:16 UTC

Câștiguri

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec. 2025, 22:15 UTC

Câștiguri

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec. 2025, 22:09 UTC

Achiziții, Fuziuni, Preluări

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 dec. 2025, 21:49 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:23 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec. 2025, 21:19 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:06 UTC

Câștiguri

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec. 2025, 21:03 UTC

Câștiguri

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparație

Modificare preț

Simulations Plus Inc Așteptări

Obiectiv de preț

By TipRanks

0.74% sus

Prognoză pe 12 luni

Medie 20.5 USD  0.74%

Maxim 25 USD

Minim 16 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSimulations Plus Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

3

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

310 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat